Microbiology and Immunology

You are here

Publications

Found 47 results

Author Title Type [ Year

]

Filters: Author is Moore, John P [Clear All Filters]

2010

Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K et al.. 2010. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.. Virology. 401(2):236-47.

Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP. 2010. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.. J Infect Dis. 202(5):739-44.

Liu J, Deng Y, Li Q, Dey AK, Moore JP, Lu M. 2010. Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.. J Virol. 84(1):201-9.

Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW. 2010. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.. J Biol Chem. 285(47):36456-70.

2009

Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD et al.. 2009. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.. Proc Natl Acad Sci U S A. 106(14):5801-6.

Dey AK, David KB, Lu M, Moore JP. 2009. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.. Virology. 385(1):275-81.

Banerjee K, Andjelic S, Klasse PJohan, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP. 2009. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.. Virology. 389(1-2):108-21.

Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP. 2009. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.

Moore JP, Kuritzkes DR. 2009. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.. Curr Opin HIV AIDS. 4(2):118-24.

Anastassopoulou CG, Ketas TJ, Klasse PJohan, Moore JP. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.. Proc Natl Acad Sci U S A. 106(13):5318-23.

W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH. 2009. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.

Kang YKenneth, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SPrasad N, Donovan GP, Dey AK, Zhu P, Roux KH et al.. 2009. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.. Vaccine. 27(37):5120-32.

Liu J, Deng Y, Dey AK, Moore JP, Lu M. 2009. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation.. Biochemistry. 48(13):2915-23.

Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. 2009. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.. PLoS Pathog. 5(8):e1000548.

2008

Klasse PJohan, Shattock R, Moore JP. 2008. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.. Annu Rev Med. 59:455-71.

Pugach P, Ketas TJ, Michael E, Moore JP. 2008. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.. Virology. 377(2):401-7.

Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP. 2008. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.. Virology. 372(1):187-200.

Veazey RS, Ketas TA, Klasse PJohan, Davison DK, Singletary M, Green LC, Greenberg ML, Moore JP. 2008. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.. Proc Natl Acad Sci U S A. 105(30):10531-6.

2007

Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP. 2007. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.. Virology. 364(2):431-40.

Dey AK, David KB, Klasse PJ, Moore JP. 2007. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.. Virology. 360(1):199-208.

2005

Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJohan, Moore JP. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.. Nat Med. 11(12):1293-4.

Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al.. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.